Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported additional share buybacks, repurchasing 190,000 shares in the open market at an average price of about $0.2805 per share.
In total, the company has repurchased 4,060,000 shares for approximately $811,000 under its up to $5 million program, which runs through December 31, 2026.
Positive
- Total 4,060,000 shares repurchased to date under the buyback program
- Approximately $811,000 deployed toward share repurchases out of up to $5 million authorization
- Buyback program remains active through December 31, 2026, with potential renewal
- Management signals belief shares are undervalued based on company fundamentals and long-term potential
Negative
- Only about $811,000 utilized so far from the up to $5 million repurchase authorization
- Future repurchase activity remains subject to market conditions, creating uncertainty on pace and scale
News Market Reaction – COSM
In the Jul 8 session, COSM gained 2.80%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.7% during that session. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Buyback expansion | Positive | -4.9% | Reported buybacks reaching 3.87M shares for about $758,000 under $5M plan. |
| Jul 07 | Revenue and buybacks | Positive | -4.9% | Preliminary record Q2 and H1 2026 revenue and ongoing $5M repurchase plan. |
| Jul 06 | Buyback increase | Positive | +13.8% | Additional 220,000-share repurchase, lifting total buybacks to 3.64M shares. |
| Jul 02 | Buyback expansion | Positive | +17.6% | 770,000-share addition lifted total repurchases to 3.42M under $5M plan. |
| Jul 01 | Initial buyback | Positive | +9.2% | Initial repurchase of 2.65M shares for $500,000 under new $5M program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent buyback headlines have produced mixed reactions, with three positive and two negative one-day moves around the announcements.
Key Terms
open market financial
sec rules 10b5-1 regulatory
10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 190,000 shares of its common stock in the open market at an average price of approximately
The Company has now repurchased a total of 4,060,000 shares for approximately
The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company’s sole discretion.
Greg Siokas, CEO of Cosmos Health, stated: “Surpassing four million shares repurchased reflects our conviction that Cosmos Health’s stock remains undervalued relative to the fundamentals and long-term potential of our business. We will continue to pursue repurchases as part of our broader commitment to building value for our shareholders.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
